ClinicalTrials.gg
CompletedNCT00319306RELEASEUpdated Mar 17, 2009

Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy

A Phase 3 interventional study of Budesonide/formoterol and Symbicort® Turbohaler® in Asthma, sponsored by AstraZeneca. Completed at 59 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-17.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
24th of 108
550 · median 124
Started
2005
with 5 others
Phase 3
51 of 110
3 open now
Registered
18th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 24th largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2005, is one of 51 in phase 3, and was the 18th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether patients with asthma are better able to manage and control their symptoms by using one inhaler daily that both prevents as well as treats the symptoms of an asthma exacerbation.

03

Conditions studied

  • Asthma

Keywords

  • Respiratory Tract Diseases
  • Bronchial Diseases
  • Anti-asthmatic agents
  • Anti-asthmatic drugs
  • Bronchodilators
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged over 18
  • Confirmed diagnosis of mild to moderate asthma by doctor
  • Currently receiving inhaled corticoid- medicine for treatment of asthma and requiring a review of current asthma treatment

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, breast-feeding, or planning pregnancy
  • Patients with a history of
  • Patients using any beta blocker therapy
  • Patients receiving tablets or steroid injections
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
550 participants

Interventions

06

What researchers measure

Primary outcomes

  1. In a real life setting, to compare Symbicort® Single Inhaler Therapy with a patient's previous therapy (including low dose ICS), by assessment of the changes in the Asthma Control Questionnaire score in uncontrolled asthmatic patients.

Secondary outcomes

  1. Change in forced expiratory volume in one second (FEV1)

  2. Change in peak expiratory flow (PEF)

  3. Patient Reported Outcomes: AQLQ(S), SATQ, RCP-3 scores

07

Study locations

59 sites
  • Research Site
    Fowey, Cornwall, United Kingdom
  • Research Site
    Hove, East Sussex, United Kingdom
  • Research Site
    Ilford, Essex, United Kingdom
  • Research Site
    Glenrothes, Fife, United Kingdom
  • Research Site
    Dartford, Kent, United Kingdom
  • Research Site
    Airdrie, Lanarkshire, United Kingdom
  • Research Site
    Hamilton, Lanarkshire, United Kingdom
  • Research Site
    Doncaster, North Yorkshire, United Kingdom
  • Research Site
    Cookstown, Northern Ireland, United Kingdom
  • Research Site
    Downpatrick, Northern Ireland, United Kingdom
  • Research Site
    Barry, South Glamorgan, United Kingdom
  • Research Site
    Chase Terrace, Staffordshire, United Kingdom
  • Research Site
    East Horsley, Surrey, United Kingdom
  • Research Site
    Crawley, West Sussex, United Kingdom
  • Research Site
    Box, Wiltshire, United Kingdom
  • Research Site
    Bradford-On-Avon, Wiltshire, United Kingdom
  • Research Site
    Ashford, United Kingdom
  • Research Site
    Atherstone, United Kingdom
  • Research Site
    Ayrshire, United Kingdom
  • Research Site
    Bath, United Kingdom
  • Research Site
    Blackpool, United Kingdom
  • Research Site
    Bolton, United Kingdom
  • Research Site
    Cardiff, United Kingdom
  • Research Site
    Carrickfergus, United Kingdom
  • Research Site
    Cheshire, United Kingdom
  • Research Site
    Chesterfield, United Kingdom
  • Research Site
    Coventry, United Kingdom
  • Research Site
    Dundee, United Kingdom
  • Research Site
    Ellesmere Port, United Kingdom
  • Research Site
    Fife, United Kingdom
  • Research Site
    Glasgow, United Kingdom
  • Research Site
    Harrow, United Kingdom
  • Research Site
    Larne, United Kingdom
  • Research Site
    Leeds, United Kingdom
  • Research Site
    Middlesborough, United Kingdom
  • Research Site
    Newcastle, United Kingdom
  • Research Site
    Newtownabbey, United Kingdom
  • Research Site
    Peterhead, United Kingdom
  • Research Site
    Pontypridd, United Kingdom
  • Research Site
    Reading, United Kingdom
  • Research Site
    Rugby, United Kingdom
  • Research Site
    Rutherglen, United Kingdom
  • Research Site
    Sandy, United Kingdom
  • Research Site
    Sheffield, United Kingdom
  • Research Site
    Stafford, United Kingdom
  • Research Site
    Stevenage, United Kingdom
  • Research Site
    Stockport, United Kingdom
  • Research Site
    Sunbury on Thames, United Kingdom
  • Research Site
    Sutton Coldfield, United Kingdom
  • Research Site
    Tilehurst, United Kingdom
  • Research Site
    Tonbridge, United Kingdom
  • Research Site
    Trowbridge, United Kingdom
  • Research Site
    Vale of Glamorgan, United Kingdom
  • Research Site
    Warminster, United Kingdom
  • Research Site
    Watford, United Kingdom
  • Research Site
    Wells next the Sea, United Kingdom
  • Research Site
    Westbury, United Kingdom
  • Research Site
    Woking, United Kingdom
  • Research Site
    Yaxley, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2006
First posted
Apr 27, 2006
Start
Sep 2005
CompletionActual
Dec 2006
Last update
Mar 17, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00319306
Lead sponsor
AstraZeneca
First posted
Apr 27, 2006
Start date
Sep 2005
Completion
Dec 2006
Last update
Mar 17, 2009

Study contacts

Iain Small, MD
principal investigator · General Practitioner
AstraZeneca UK Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion